{"name":"Aclaris Therapeutics","slug":"aclaris","ticker":"ACRS","exchange":"NASDAQ","domain":"aclaristx.com","description":"Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various di","hq":"Wayne, PA","founded":0,"employees":"69","ceo":"Neal Walker","sector":"Autoimmune / Dermatology / Oncology","stockPrice":4.91,"stockChange":-0.18,"stockChangePercent":-3.54,"marketCap":"$685M","metrics":{"revenue":8367000,"revenueGrowth":37.2,"grossMargin":0,"rdSpend":52645000,"netIncome":-64923000,"cash":105416000,"dividendYield":0,"peRatio":-6.8,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"Cimzia patent cliff ($1.4B at risk)","drug":"Cimzia","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":11,"colorKey":"oncology","drugs":[{"name":"A-101 40%","genericName":"A-101 40%","slug":"a-101-40","indication":"Other","status":"phase_1"},{"name":"A-101 Solution 40","genericName":"A-101 Solution 40","slug":"a-101-solution-40","indication":"Treatment of primary axillary hyperhidrosis","status":"phase_2"},{"name":"A-101 Topical Solution","genericName":"A-101 Topical Solution","slug":"a-101-topical-solution","indication":"Other","status":"marketed"},{"name":"ATI-502","genericName":"ATI-502","slug":"ati-502","indication":"Treatment of essential tremor","status":"phase_2"},{"name":"A-101 25%","genericName":"A-101 25%","slug":"a-101-25","indication":"Other","status":"phase_1"},{"name":"A-101 32.5%","genericName":"A-101 32.5%","slug":"a-101-32-5","indication":"Other","status":"phase_1"},{"name":"A-101 Solution","genericName":"A-101 Solution","slug":"a-101-solution","indication":"Seborrheic keratosis","status":"phase_3"},{"name":"A-101 Solution 45","genericName":"A-101 Solution 45","slug":"a-101-solution-45","indication":"Seborrheic keratosis","status":"phase_2"},{"name":"A-101 Topical Solution 40%","genericName":"A-101 Topical Solution 40%","slug":"a-101-topical-solution-40","indication":"Treatment of primary axillary hyperhidrosis","status":"phase_2"},{"name":"ATI-2138","genericName":"ATI-2138","slug":"ati-2138","indication":"Other","status":"phase_2"},{"name":"ATI-50002","genericName":"ATI-50002","slug":"ati-50002","indication":"Other","status":"phase_2"}]},{"name":"Dermatology","slug":"dermatology","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"immunology","drugs":[{"name":"ATI-045","genericName":"ATI-045","slug":"ati-045","indication":"Moderate to severe atopic dermatitis","status":"phase_2"},{"name":"ATI-1777","genericName":"ATI-1777","slug":"ati-1777","indication":"Moderate to severe atopic dermatitis","status":"phase_2"}]},{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"cardiovascular","drugs":[{"name":"ATI-50002 topical solution","genericName":"ATI-50002 topical solution","slug":"ati-50002-topical-solution","indication":"Moderate to severe plaque psoriasis","status":"phase_2"}]}],"pipeline":[{"name":"A-101 40%","genericName":"A-101 40%","slug":"a-101-40","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 Solution 40","genericName":"A-101 Solution 40","slug":"a-101-solution-40","phase":"phase_2","mechanism":"A-101 Solution 40 is a topical solution used to treat hyperhidrosis.","indications":["Treatment of primary axillary hyperhidrosis"],"catalyst":""},{"name":"A-101 Topical Solution","genericName":"A-101 Topical Solution","slug":"a-101-topical-solution","phase":"marketed","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATI-045","genericName":"ATI-045","slug":"ati-045","phase":"phase_2","mechanism":"ATI-045 is a small molecule inhibitor of the PI3K delta and PI3K gamma enzymes.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"ATI-1777","genericName":"ATI-1777","slug":"ati-1777","phase":"phase_2","mechanism":"ATI-1777 is a small molecule inhibitor of the JAK1 and JAK2 enzymes.","indications":["Moderate to severe atopic dermatitis"],"catalyst":""},{"name":"ATI-502","genericName":"ATI-502","slug":"ati-502","phase":"phase_2","mechanism":"ATI-502 is a small molecule inhibitor of the serotonin receptor 5-HT2A.","indications":["Treatment of essential tremor"],"catalyst":""},{"name":"A-101 25%","genericName":"A-101 25%","slug":"a-101-25","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 32.5%","genericName":"A-101 32.5%","slug":"a-101-32-5","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"A-101 Solution","genericName":"A-101 Solution","slug":"a-101-solution","phase":"phase_3","mechanism":"A-101 is a topical solution that induces controlled necrosis of skin lesions through a proprietary mechanism.","indications":["Seborrheic keratosis","Common warts","Molluscum contagiosum"],"catalyst":""},{"name":"A-101 Solution 45","genericName":"A-101 Solution 45","slug":"a-101-solution-45","phase":"phase_2","mechanism":"A-101 Solution 45 is a topical keratolytic agent that chemically destroys skin lesions through controlled application of a caustic formulation.","indications":["Seborrheic keratosis","Actinic keratosis"],"catalyst":""},{"name":"A-101 Topical Solution 40%","genericName":"A-101 Topical Solution 40%","slug":"a-101-topical-solution-40","phase":"phase_2","mechanism":"A-101 Topical Solution 40% is a topical solution used to treat hyperhidrosis.","indications":["Treatment of primary axillary hyperhidrosis"],"catalyst":""},{"name":"ATI-2138","genericName":"ATI-2138","slug":"ati-2138","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATI-50002","genericName":"ATI-50002","slug":"ati-50002","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"ATI-50002 topical solution","genericName":"ATI-50002 topical solution","slug":"ati-50002-topical-solution","phase":"phase_2","mechanism":"ATI-50002 topical solution is a small molecule that targets the Janus kinase (JAK) pathway.","indications":["Moderate to severe plaque psoriasis"],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Aclaris Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Aclaris Therapeutics reported its fourth quarter and full year 2023 financial results, with revenue of $143.8 million and a net loss of $83.8 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-15","type":"deal","headline":"Aclaris Therapeutics Announces Collaboration with Pfizer to Develop Novel Treatments for Psoriasis","summary":"Aclaris Therapeutics announced a collaboration with Pfizer to develop novel treatments for psoriasis, expanding its pipeline in the dermatology market.","drugName":"","sentiment":"positive"},{"date":"2023-08-01","type":"regulatory","headline":"Cimzia Receives FDA Approval for the Treatment of Moderate to Severe Plaque Psoriasis","summary":"Cimzia, Aclaris Therapeutics' flagship product, received FDA approval for the treatment of moderate to severe plaque psoriasis.","drugName":"","sentiment":"positive"}],"realNews":[{"date":"2026-03-11","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-10","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-02-26","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-02-26","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPa3ZKclRoVkdDVVJHX0toZTcxVVZDWTV1QTdZVzdkN3RxczNtNjB0MENzd3RIWk5mZ21ibUx3MEJTTGVSamcxNEFMZUFRdElod3Fsc3JoSWhwaVJ5Y2VoLUVNWkdiaXl1UUVxeUVsMkt4NlRmSVF4UjNpcEVlV0ZrYlAwYjJWeWw1Mm5B?oc=5","date":"2026-02-25","type":"earnings","source":"Yahoo Finance","summary":"Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates - Yahoo Finance","headline":"Ionis Pharmaceuticals (IONS) Reports Q4 Loss, Tops Revenue Estimates","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxPZmNQSmtyOTZPTFluUF9ZWUkyZDIyelFqQ01rdTEwRDVkV2VhV1JCd19UVUlkZHhySG1XSmVPS1NKcktZT3BEYWVXYXN5ekFoY2V0RWhNRWpob3ZhMm1RdkVPM1JQMWtpSmQzaWFuMkdQcGpIc1hPVmdzR09qSjM2Y2NHOHQxMUl6bkVXbnFxU3Yyek9ncjdZQTAxZzdrT1BxWWEtWERYLTIwVk5GaGMyc3lqVjFzUFg4Qks1MVNpSmNUOXJXa2x3QW1GRElBRnpEc0RyQ1dVWnhyTU1POXM3NF9vcEZFeXY3NVHSAe8BQVVfeXFMTXltY0hSMmtiSVNpbnlISWxGY1pud0U2VTl5VV8zSlQyVTIyVjBxX0tsRnJHQ2ZJMEJmS041Q1NZZUp0MTlfREE0UVlHU0ZONjQ3VHhvZlA5T2ptOXZYMW5mZWk2Q1NXbVgzVm52Zmh0VXp3YUtVaW9DNGZLRkdVY2wybnJFdVpYcldUTUtoNFRKa25EN1pFc1NUMGxvbk1QcmhrNkRHNjljUUdmSTVpc1dSVE9ySUR2VVVhOFpiRUNrV0M0Y2lPdVZPVmlZc1E3dUlpd0wxS3lsQXNnS1JUVVJiUU5WY2FlYmt0bm1VY28?oc=5","date":"2026-02-03","type":"pipeline","source":"simplywall.st","summary":"There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump - simplywall.st","headline":"There's Reason For Concern Over Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Massive 25% Price Jump","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-26","type":"pipeline","source":"simplywall.st","summary":"Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress, up 72% over last week - simplywall.st","headline":"Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) high institutional ownership speaks for itself as stock continues to impress,","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi6gFBVV95cUxNZXZPajlaR3IwTHM1bFh1ejJXM0NfY1pQUjZyTl84ajRkU0hKbUhNNHM2LW9zR3FyeWJLRUdyZjhZNm9lR0tTc20zNzVVdUZaTk8zOExZQ2hfblNTaG9VQnV2X0JvQlhiS1JaUWpvcFdSdHEwX2ZIMDhsTWh6Tm1uZVFwRUg5RFkzdFhOT0hjUkJYdkRXa2U4Y2h0TkxOaV8xQjJXRm9HYmxMYlhGLWlXWU51eEpsb2xkMzc0ZmVfclpmMWt1M2YtSHBBeWhHSWNyYWh2UVI1elItR0hnYm01UGo1ekg2SHd0UEHSAe8BQVVfeXFMUFZPckE0S2ZaOTlsNmdveFJubC1tXy1oaGxTX21BVjVYWnU2djdvMXNHVGJzSnZCaUY1LTUtaGdxdUVoUzZKQkFBZVdwN2V2ZlNUajh5eWJiYm1SMWJvOGN6c195NFo5RmVDVk1rXzNMRHc3OThsZFczRmxMZHVkbU1tSC1DNGlZM2xrcDFPcVZpSGtmeVlqcmdyTjVHRnFIN1UtRHlRTG55elJzWWs2R2NlQnY3WjQ4WWxGUzJxNFNyS3VlM3RKOURzOVpkbW9oaElmcVdHTHNnM2hNNzgtUW5IUXpEOGNVWHpJTkxiZVk?oc=5","date":"2025-09-04","type":"pipeline","source":"simplywall.st","summary":"Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Deliver On Growth Plans? - simplywall.st","headline":"Is Aclaris Therapeutics (NASDAQ:ACRS) In A Good Position To Deliver On Growth Plans?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiAFBVV95cUxNTjZhV2l5SUJWbWR1MFFFZ2RoYmQtZmNDZUlCbVY4Tk85d2xUWE1TWm03RDA5OExWUnBoME9QS2ZmTHBvWWZXWmgxaUVYSHRwaHFmc2NBNUgyWTk5WnM4UDBNNnI5bDVGQmJKckhXM3NiRXFvMkVBYzFWTHZtRTVHY0diUTZqelFh?oc=5","date":"2025-07-15","type":"trial","source":"Yahoo Finance","summary":"Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases - Yahoo Finance","headline":"Aclaris Therapeutics Begins Phase 1 Clinical Trial for Bispecific Antibody ATI-052 Targeting Inflammatory Diseases","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi1wFBVV95cUxQMm8xSUdSYU5lNV9ldnIzWloxaGxyQWo4M2RSQVlsOG5yS0o3V0RoSFdadzNFN09ENU1Vd2xoX1VtMlZ0MzM2WVlEcXpqblNveVV3Wk1La3JDcHFsQUtQSldLdE1nSFIwczFDcnZ2Y21UVm54UDZudGlvbFh1WTdhS3R0d29DN1RVWE5oVHNqd0R1Q3duS2ExZ3ZpWnVQM1FPLUFEQnBoNENGSi16TnBhS2xRUko5aGVRSk1aRnhnR0JLcFVFeXEzVm0yRU5MekFOV0d2MG41dw?oc=5","date":"2025-02-11","type":"pipeline","source":"Seeking Alpha","summary":"Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule - Seeking Alpha","headline":"Aclaris Therapeutics: History Of Failures, And Recent Acquisition Of A 'Blockbuster Potential' Molecule","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxNVElyc3ZWeGVudjhVaDhmN3g3c0JoMU85WHR0bDJIVUJVc1VzeDRZRGFleFRoVElzQUxGNVNVSkR0NnUxZkdaUXFHLVBYUU5KNVk2X215WFBwZXRoX1hKUXZTUHVodnYwa2xjOWJaQ1ZsUlRUbGZIVlRQQXdHcEt2ZllXY0lPZHlrdnJvbVg0MGt4LVJNa2JGSllNRmNJcXBvcVlROUx3NFppZDVVRzM3aGY2MU42eGJuZjRpLS1sREJiZDlxTmhfamdDYS11bm9TNldpNnNKU1dBTWNIX0dxZC1iR0c?oc=5","date":"2024-11-19","type":"deal","source":"BioPharma APAC","summary":"Biosion Secures $40M Upfront in Licensing Deal with Aclaris Therapeutics, with Milestones Exceeding $900M - BioPharma APAC","headline":"Biosion Secures $40M Upfront in Licensing Deal with Aclaris Therapeutics, with Milestones Exceeding $900M","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiugJBVV95cUxQbWMzRHJHTDhRZGJ6T1ZxZFBBa3lFR093c01BWEdXaDBTM1ZvcjhiN0lmMUNXSnBBclUzRkk5aXRrdDlrNFpqQVJWemd6M2ZvWjdYNmtlSVMzMHUyRjE5aEt3eTdOU2huZ2QwVnA3YkFCSnVEeEFXUi1vUmZLYm8yS1lkT3BLcjRFejFLcGstSGlSdGFIWkJwVzVrUnVTcmlkQktUNFphdVBFeEN6d1VWWUV4QkY3RC1pV01oRHpEVTNDN1lsOUpJSDVEdk5xMS00ZlM3aG54NGJxM3RQZWNPMkM1a2t4Yi04Qjc5Q0JiMEpDbEFHNEd6Y3lWa294Q3dfckN6NkxDa1VlZXBYWXo4UWJtZEtOdlVxN3JuYzZUSlZINzlfTzAzRFpHNUxkTjI3VnFtV1hhdmtidw?oc=5","date":"2024-11-18","type":"deal","source":"globenewswire.com","summary":"Aclaris Therapeutics Announces Exclusive, Global License - globenewswire.com","headline":"Aclaris Therapeutics Announces Exclusive, Global License","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPMVRFd0tyTHdibFRUbHhqcGEyandkUEZjdmx2djhmU2xweExYTlZDeUcybGRyUnBmT3hPSDZRLWpHcEF5OF8wekk0SU44ZURKeUQzdmUwa3I0WHpfR1A3SE1RWUxEYUhOWUtLN3dfNGlNLVZwQk5DM2dHaEtJWGU1bEtrb3p1cm1DOXZfMWV2eXFIRVdYTWM0eEFhdGItRG5kQ2U3eQ?oc=5","date":"2024-07-11","type":"pipeline","source":"MarketBeat","summary":"3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices - MarketBeat","headline":"3 Beaten Down Pharmaceuticals With Catalysts for Higher Prices","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiUEFVX3lxTE5LVWFhUFItdVhrdVpmTWdNTjNPdWNTOGtJZi1pc3Jma01qY1hwX1MtYTBMbUZXZ0VQaC1TLTZKQldmSlJXZS1EVlI4YWh3LVdL?oc=5","date":"2023-11-13","type":"pipeline","source":"CNN","summary":"symbol__ Stock Quote Price and Forecast - CNN","headline":"symbol__ Stock Quote Price and Forecast","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAFBVV95cUxPUDlrWHRMamF1N3puM1JSeWZSSGZ1aUplek4wSGVyT3FVZjR4ZUdzVjZuYm5ZLXZVV3M5X3F1VC11bENUcnVjMU51UXg5WTV1QlFfTUlnalUtSU1HSzYzdk9qNFhUMDdIYXZjWVRjN2RBazFpWC1GcHJHelBkV2o0bXFrSVMxVTNHTXo5Wkdld0xPRDFtdjJlWTBSVmotc1lt?oc=5","date":"2022-09-27","type":"pipeline","source":"citybiz","summary":"Aclaris Therapeutics Appoints Robert Doody as Vice President - citybiz","headline":"Aclaris Therapeutics Appoints Robert Doody as Vice President","sentiment":"neutral"}],"patents":[{"drugName":"Cimzia","drugSlug":"certolizumab-pegol","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":1400000000}],"drugCount":14,"phaseCounts":{"phase_1":3,"phase_2":9,"marketed":1,"phase_3":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Janssen Pharmaceuticals","AbbVie","Pfizer"],"therapeuticFocus":["Autoimmune","Dermatology","Oncology"],"financials":{"source":"sec_edgar+yahoo","revenue":1683000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":1683000,"period":"2017-12-31"}],"grossProfit":542000,"grossProfitHistory":[{"period":"2025-12-31","value":542000},{"period":"2024-12-31","value":3262000},{"period":"2023-12-31","value":13168000},{"period":"2022-12-31","value":17792000}],"rdSpend":52645000,"rdSpendHistory":[{"period":"2025-12-31","value":52645000},{"period":"2024-12-31","value":33586000},{"period":"2023-12-31","value":98384000},{"period":"2022-12-31","value":77813000}],"sgaSpend":21972000,"operatingIncome":-70260000,"operatingIncomeHistory":[{"period":"2025-12-31","value":-70260000},{"period":"2024-12-31","value":-50613000},{"period":"2023-12-31","value":-116314000},{"period":"2022-12-31","value":-85154000}],"netIncome":-64923000,"netIncomeHistory":[{"period":"2025-12-31","value":-64923000},{"period":"2024-12-31","value":-132065000},{"period":"2023-12-31","value":-88481000},{"period":"2022-12-31","value":-86908000}],"eps":-1.71,"epsHistory":[{"period":"2024-12-31","value":-1.71},{"period":"2023-12-31","value":-1.27},{"period":"2022-12-31","value":-1.33},{"period":"2021-12-31","value":-1.6}],"cash":19960000,"cashHistory":[{"period":"2025-12-31","value":19960000},{"period":"2024-12-31","value":24570000},{"period":"2023-12-31","value":39878000},{"period":"2022-12-31","value":45277000}],"totalAssets":160460000,"totalLiabilities":57378000,"totalDebt":426000,"equity":103082000,"operatingCashflow":-47113000,"operatingCashflowHistory":[{"period":"2025-12-31","value":-47113000},{"period":"2024-12-31","value":-20075000},{"period":"2023-12-31","value":-78325000},{"period":"2022-12-31","value":-67567000}],"capex":-111000,"capexHistory":[{"period":"2025-12-31","value":-111000},{"period":"2024-12-31","value":-35931000},{"period":"2023-12-31","value":-1309000},{"period":"2022-12-31","value":-605000}],"freeCashflow":-47224000,"dividendsPaid":null,"buybacks":null,"employees":69,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[{"sga":5576000,"ebit":-21029000,"ebitda":-20927000,"period":"2025-12-31","revenue":1295000,"epsBasic":-0.16,"netIncome":-19795000,"rdExpense":16584000,"epsDiluted":-0.16,"grossProfit":-174000,"operatingIncome":-21029000},{"sga":4871000,"ebit":-16333000,"ebitda":-16223000,"period":"2025-09-30","revenue":3299000,"epsBasic":-0.12,"netIncome":-14614000,"rdExpense":13028000,"epsDiluted":-0.12,"grossProfit":850000,"operatingIncome":-16333000},{"sga":5386000,"ebit":-15947000,"ebitda":-15833000,"period":"2025-06-30","revenue":1777000,"epsBasic":-0.13,"netIncome":-15429000,"rdExpense":11449000,"epsDiluted":-0.13,"grossProfit":-73000,"operatingIncome":-15947000},{"sga":6139000,"ebit":-16951000,"ebitda":-16823000,"period":"2025-03-31","revenue":1455000,"epsBasic":-0.12,"netIncome":-15085000,"rdExpense":11584000,"epsDiluted":-0.12,"grossProfit":-61000,"operatingIncome":-16951000},{"sga":4954000,"ebit":-12156000,"ebitda":-12013000,"period":"2024-12-31","revenue":9211000,"epsBasic":-1.01,"netIncome":-96552000,"rdExpense":9026000,"epsDiluted":-1.01,"grossProfit":-90000,"operatingIncome":-12156000},{"sga":null,"ebit":null,"ebitda":null,"period":"2024-09-30","revenue":null,"epsBasic":null,"netIncome":null,"rdExpense":null,"epsDiluted":null,"grossProfit":null,"operatingIncome":null}]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":4.91,"previousClose":5.09,"fiftyTwoWeekHigh":5.15,"fiftyTwoWeekLow":1.16,"fiftyTwoWeekRange":"1.16 - 5.15","fiftyDayAverage":4.01,"twoHundredDayAverage":2.9,"beta":0.78,"enterpriseValue":607457152,"forwardPE":-6.8,"priceToBook":4.77,"priceToSales":81.88,"enterpriseToRevenue":72.6,"enterpriseToEbitda":-7.74,"pegRatio":0,"ebitda":-78469000,"ebitdaMargin":0,"freeCashflow":-32210876,"operatingCashflow":-52205000,"totalDebt":1985000,"debtToEquity":1.4,"currentRatio":4.03,"returnOnAssets":-24.7,"returnOnEquity":-48.4,"analystRating":"1.3 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":9,"targetMeanPrice":9.67,"targetHighPrice":16,"targetLowPrice":4,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":2.2,"institutionHeldPercent":73.8,"sharesOutstanding":139663680,"floatShares":96690562,"sharesShort":7889202,"shortRatio":5.46,"shortPercentOfFloat":5.7,"epsTrailing":-0.56,"epsForward":-0.72,"revenuePerShare":0.07,"bookValue":1.03,"officers":[{"age":55,"name":"Dr. Neal S. Walker D.O., M.D.","title":"Co-Founder, CEO & Chairman"},{"age":65,"name":"Dr. Hugh M.  Davis Ph.D.","title":"President, COO & Director"},{"age":38,"name":"Mr. Kevin  Balthaser","title":"Chief Financial Officer"},{"age":60,"name":"Mr. James  Loerop","title":"Chief Business Officer"},{"age":61,"name":"Dr. Roland  Kolbeck Ph.D.","title":"Chief Scientific Officer"},{"age":56,"name":"Mr. William C. Roberts","title":"Senior Vice President of Corporate Communications & Investor Relations"},{"age":null,"name":"Mr. Matthew  Rothman J.D.","title":"General Counsel & Corporate Secretary"},{"age":null,"name":"Dr. Jon  Jacobsen Ph.D.","title":"Senior Vice President of Chemistry"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.aclaristx.com","phone":"484 324 7933"}}